Literature DB >> 24477978

Fetal renin-angiotensin-system blockade syndrome: renal lesions.

Caroline Plazanet1, Christelle Arrondel, François Chavant, Marie-Claire Gubler.   

Abstract

BACKGROUND: Fetuses exposed to angiotensin-converting enzyme inhibitors or angiotensin receptor antagonists during the second and/or third trimesters of gestation are at high risk of developing severe complications. They consist in fetal hypotension, and anuria/oligohydramnios leading to Potter sequence, frequently associated with hypocalvaria. Most fetuses die during the pre- or postnatal period, whereas others recover normal or subnormal renal function. However, the secondary occurrence of renal failure or hypertension has been reported in children after apparent complete recovery.
METHODS: In this context, we analyzed renal lesions in 14 fetus/neonates who died soon after exposure to renin-angiotensin-system (RAS) blockers. Our objective was to determine the causes for the persistence or the secondary occurrence of renal complications reported in some of the survivors.
RESULTS: As previously described, renal tubular dysgenesis is usually observed. Additional lesions, such as thickening of the muscular wall of arterioles and interlobular arteries, glomerular cysts, and interstitial fibrosis, develop early during fetal life.
CONCLUSION: We suggest that renal lesions that develop before birth may persist after withdrawal of the causative drugs and normalization of blood and renal perfusion pressure. Their persistence could explain the severe long-term outcome of some of these patients. Long-term study of children exposed to RAS blockers during fetal life is strongly recommended.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24477978     DOI: 10.1007/s00467-013-2749-4

Source DB:  PubMed          Journal:  Pediatr Nephrol        ISSN: 0931-041X            Impact factor:   3.714


  25 in total

1.  Aberrant renal vascular morphology and renin expression in mutant mice lacking angiotensin-converting enzyme.

Authors:  K F Hilgers; V Reddi; J H Krege; O Smithies; R A Gomez
Journal:  Hypertension       Date:  1997-01       Impact factor: 10.190

2.  Prognosis and outcome of pregnancies exposed to renin-angiotensin system blockers.

Authors:  Emmanuel Spaggiari; Laurence Heidet; Gilles Grange; Fabien Guimiot; Sophie Dreux; Anne-Lise Delezoide; Françoise Muller
Journal:  Prenat Diagn       Date:  2012-08-18       Impact factor: 3.050

3.  Foetal kidney maldevelopment in maternal use of angiotensin II type I receptor antagonists.

Authors:  Farida Daïkha-Dahmane; Evelyne Levy-Beff; Myriam Jugie; Richard Lenclen
Journal:  Pediatr Nephrol       Date:  2006-03-25       Impact factor: 3.714

4.  Exposure to candesartan during the first trimester of pregnancy in type 1 diabetes: experience from the placebo-controlled DIabetic REtinopathy Candesartan Trials.

Authors:  M Porta; J W Hainer; S-O Jansson; A Malm; R Bilous; N Chaturvedi; J H Fuller; R Klein; T Orchard; H-H Parving; A-K Sjølie
Journal:  Diabetologia       Date:  2011-01-12       Impact factor: 10.122

Review 5.  Fetal toxic effects of angiotensin II receptor antagonists: case report and follow-up after birth.

Authors:  Marie-Andrée Bos-Thompson; Dominique Hillaire-Buys; Françoise Muller; Hervé Dechaud; Evelyne Mazurier; Pierre Boulot; Denis Morin
Journal:  Ann Pharmacother       Date:  2004-12-08       Impact factor: 3.154

6.  Pregnancy outcome after in utero exposure to angiotensin converting enzyme inhibitors or angiotensin receptor blockers.

Authors:  Orna Diav-Citrin; Svetlana Shechtman; Yehudit Halberstadt; Victoriya Finkel-Pekarsky; Rebecka Wajnberg; Judy Arnon; Elena Di Gianantonio; Maurizio Clementi; Asher Ornoy
Journal:  Reprod Toxicol       Date:  2011-02-18       Impact factor: 3.143

7.  Angiotensin II promotes development of the renal microcirculation through AT1 receptors.

Authors:  Kirsten Madsen; Niels Marcussen; Michael Pedersen; Gitte Kjaersgaard; Carie Facemire; Thomas M Coffman; Boye L Jensen
Journal:  J Am Soc Nephrol       Date:  2010-01-07       Impact factor: 10.121

8.  Angiotensin-converting enzyme inhibitor fetopathy: long-term outcome.

Authors:  Guido F Laube; Markus J Kemper; Gregor Schubiger; Thomas J Neuhaus
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  2007-02-06       Impact factor: 5.747

Review 9.  Renal tubular dysgenesis.

Authors:  Marie-Claire Gubler
Journal:  Pediatr Nephrol       Date:  2013-05-01       Impact factor: 3.714

10.  Salt-losing nephrogenic diabetes insipidus caused by fetal exposure to angiotensin receptor blocker.

Authors:  Kenichiro Miura; Takashi Sekine; Atsuko Iida; Kazuhiro Takahashi; Takashi Igarashi
Journal:  Pediatr Nephrol       Date:  2009-01-20       Impact factor: 3.714

View more
  4 in total

1.  Patterns of differentiation of renin lineage cells during nephrogenesis.

Authors:  Friederike Kessel; Anne Steglich; Linda Hickmann; Ricardo Lira Martinez; Michael Gerlach; Maria Luisa S Sequeira-Lopez; R Ariel Gomez; Christian P M Hugo; Vladimir T Todorov
Journal:  Am J Physiol Renal Physiol       Date:  2021-08-02

2.  Prenatal hypocalvaria after prolonged intrauterine exposure to angiotensin II receptor antagonists.

Authors:  Marine Lallemant; Sarah Prévost; François Nobili; Didier Riethmuller; Rajeev Ramanah; Marie-France Seronde; Nicolas Mottet
Journal:  J Renin Angiotensin Aldosterone Syst       Date:  2018 Oct-Dec       Impact factor: 1.636

3.  A Premature Baby with Severe Oligohydramnios and Hypotension: a Case Report of Renal Tubular Dysgenesis.

Authors:  Jeesu Min; Myung Hyun Cho; Seong Phil Bae; Seung Han Shin; Il Soo Ha; Hae Il Cheong; Hee Gyung Kang
Journal:  J Korean Med Sci       Date:  2020-08-17       Impact factor: 2.153

4.  Adverse pregnancy outcomes associated with first-trimester exposure to angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers: A systematic review and meta-analysis.

Authors:  Nida Buawangpong; Supanimit Teekachunhatean; Nut Koonrungsesomboon
Journal:  Pharmacol Res Perspect       Date:  2020-10
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.